Improved Factor VIII Inhibitor Evaluation

Withdrawn before enrolling

Conditions studied: Hemophilia, Hemophilia A

In brief

Commercial one and two-stage factor VIII assays may not detect some clinically significant inhibitor antibodies. The purpose of the proposed study is to standardize and validate a platelet-based factor VIII activity assay with greater sensitivity to clinically important inhibitory antibodies. Investigators will evaluate the platelet-dependent inhibitory activity vs. conventional inhibitory activity in stored patient plasmas and correlate to bleeding histories

Key facts

Study ID

NCT02726139

Run by

Boston VA Research Institute, Inc.

People needed

0

Starts

2016-07-15

Expected to finish

2021-01-25

Last updated by the study team

2021-02-25

Who can join

Age: any. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• hemophilia A
• presence of inhibitory antibodies

You may not qualify if…

• none

Where it is running

• Boston VA Research Institute (BVARI) — Boston, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.